Gaeta Therapeutics

Executive Summary

Gaeta Therapeutics, a UK-based private biopharmaceutical company founded in 2017, is focused on advancing interleukin-12 (IL-12) combination therapies with checkpoint inhibitors for cancer treatment. Originating from intellectual property licensed from the University of Zurich, the company aims to harness the potent immunostimulatory properties of IL-12 to overcome resistance to checkpoint blockade. IL-12 has shown promise in preclinical models by promoting antitumor immunity and remodeling the tumor microenvironment, but its clinical development has historically been limited by systemic toxicity. Gaeta's approach may involve novel delivery or engineering strategies to enhance the therapeutic index. The company operates in the competitive immuno-oncology space, with a pipeline still in early stages (no disclosed clinical programs). Despite limited public information, the scientific rationale for IL-12 combinations remains strong, and Gaeta's focus on this cytokine could address unmet needs in solid tumors that are unresponsive to current immunotherapies. The company's ability to secure funding and advance its lead candidate toward clinical trials will be critical for value creation.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead IL-12 Combination Candidate30% success
• TBDPartnership or Licensing Deal for IL-12 Platform20% success